We're pleased to share this announcement about the positive Phase 1 trial results of the first in-humans study of BioCryst's ALK-2 Inhibitor for the treatment of FOP. Read BioCryst's press release.
Do you like this post?
We're pleased to share this announcement about the positive Phase 1 trial results of the first in-humans study of BioCryst's ALK-2 Inhibitor for the treatment of FOP. Read BioCryst's press release.
